Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Scholarships

University of British Columbia

$17,500.00

The Role of Topologically Associating Domains in Defining Regions of Epigenetic Silencing in Synovial Sarcoma

EF 2016-17

Résumé
Synovial sarcoma is a highly aggressive soft-tissue cancer that predominantly affects adolescents and young adults. This malignancy, which accounts for 10% to 20% of soft-tissues sarcomas in such a young population, has limited sensitivity to conventional chemotherapies and thus a poor survival rate. Synovial sarcomas are characterized by a unique chromosomal abnormality that ultimately dysregulates critical genes via epigenetic modifications. Epigenetic modifications are essentially changes in the control of genetic material that do not alter the genetic code itself. The exact mechanism of how this abnormal process occurs in synovial sarcoma is not yet fully understood. To shed light on this mystery, it is prudent to examine topologically associating domains (TADs), the three-dimensional organization of chromosomes. This level of analysis has only recently become feasible using new technologies. I hypothesize that TADs define regions of epigenetic silencing in synovial sarcoma that repress CDKN2A, EGR1, TP53 (tumor suppressors) and regulators of mesenchymal differentiation. To study this, I will use synovial sarcoma tissue samples from patients to profile the epigenetic changes that occur in these tumors, look for patterns using bioinformatic techniques, and carry out validation studies. By understanding the role of TADs in synovial sarcomas, we hope to guide the use of emerging epigenetic therapeutic agents in the treatment of this disease.
Programme
Master's Award: Canada Graduate Scholarships
Emplacement
British Columbia, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
367297
Name
Qiu Alvin
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
The Role of Topologically Associating Domains in Defining Regions of Epigenetic Silencing in Synovial Sarcoma
Programtype2
Studentship Programs
Orgnameinp2
University of British Columbia
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Cancer; Dna Methylation; Epigenetics; Epigenomics; Histone Modification; Synovial Sarcoma; Topologically Associating Domains
Abstract
Synovial sarcoma is a highly aggressive soft-tissue cancer that predominantly affects adolescents and young adults. This malignancy, which accounts for 10% to 20% of soft-tissues sarcomas in such a young population, has limited sensitivity to conventional chemotherapies and thus a poor survival rate. Synovial sarcomas are characterized by a unique chromosomal abnormality that ultimately dysregulates critical genes via epigenetic modifications. Epigenetic modifications are essentially changes in the control of genetic material that do not alter the genetic code itself. The exact mechanism of how this abnormal process occurs in synovial sarcoma is not yet fully understood. To shed light on this mystery, it is prudent to examine topologically associating domains (TADs), the three-dimensional organization of chromosomes. This level of analysis has only recently become feasible using new technologies. I hypothesize that TADs define regions of epigenetic silencing in synovial sarcoma that repress CDKN2A, EGR1, TP53 (tumor suppressors) and regulators of mesenchymal differentiation. To study this, I will use synovial sarcoma tissue samples from patients to profile the epigenetic changes that occur in these tumors, look for patterns using bioinformatic techniques, and carry out validation studies. By understanding the role of TADs in synovial sarcomas, we hope to guide the use of emerging epigenetic therapeutic agents in the treatment of this disease.
Competitiondate
201612
Approvedterm2
1 yr 0 mth
Pinamesdelim
Qiu, Alvin
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~